Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JX3U | ISIN: US8684591089 | Ticker-Symbol: S49
Tradegate
28.03.24
20:40 Uhr
31,400 Euro
-0,200
-0,63 %
1-Jahres-Chart
SUPERNUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SUPERNUS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
31,20032,00028.03.
31,40031,80028.03.

Aktuelle News zur SUPERNUS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoSupernus Pharmaceuticals exec sells over $500k in stock1
22.03.Supernus Pharmaceuticals exec sells $14.1k in stock1
15.03.Supernus Pharmaceuticals executive sells over $2.1m in stock3
06.03.Supernus Pharmaceuticals, Inc.: Supernus to Participate in Two Upcoming Investor Conferences1
06.03.Earnings call: Supernus Pharmaceuticals reports growth despite challenges3
28.02.Supernus Pharmaceuticals, Inc.: Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference1
28.02.Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript2
28.02.Supernus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary1
27.02.Supernus Pharmaceuticals GAAP EPS of $0.02 beats by $0.04, revenue of $164.3M beats by $9.27M2
27.02.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report1
27.02.SUPERNUS PHARMACEUTICALS, INC. - 10-K, Annual Report1
27.02.Supernus Pharmaceuticals, Inc.: Supernus Announces Fourth Quarter and Full Year 2023 Financial Results155Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year...
► Artikel lesen
13.02.Supernus Pharmaceuticals, Inc.: Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 20241
05.02.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report1
05.02.Supernus Pharmaceuticals, Inc.: Supernus Wins Infringement and Validity Case on Trokendi XR against Torrent217ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
► Artikel lesen
20.12.23Knight secures rights for ADHD treatment Qelbree from Supernus2
19.12.23Knight Therapeutics Inc: Knight Therapeutics licenses Qelbree from Supernus2
19.12.23Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada180MONTREAL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive...
► Artikel lesen
23.11.23DelveInsight Business Research, LLP: Spasticity Market Likely to Exhibit Substantial Growth by 2032, Predicts DelveInsight | Key Pharma Companies - Saol, Jazz, Supernus, Solstice Neurosciences, Ipsen, Merz, Motric Bio, SwanBio599The spasticity market is expected to grow due to factors like an increase in the patient pool and the expected entry of emerging therapies. LAS VEGAS, Nov. 23, 2023 /PRNewswire/ -- DelveInsight's...
► Artikel lesen
09.11.23Earnings call: Supernus Pharmaceuticals posts strong Q3 results on growth products, revises full-year guidance3
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1